Skip to main content

Inside the obesity drug revolution

Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.

included in this trendline
  • Novo obesity drug protects heart health in large trial
  • New kind of obesity drug sets ‘high bar’ in mid-stage study
  • Lilly’s fortunes rise on back-to-back success for obesity, Alzheimer’s drugs
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.